Burosumab-Twza Injection (Crysvita®)

Covered only for FDA‑approved X‑linked hypophosphatemia (XLH); other uses (including oncology) are excluded. Initial and 12‑month renewals require endocrinologist/nephrologist prescribing/consultation, pre‑treatment documentation of low serum phosphorus plus either low TmP/GFR or a PHEX mutation, and for adults evidence of XLH symptoms and trial of (or contraindication to) oral phosphate/calcitriol; dosing limited to ≤90 mg SC every ≥4 weeks for adults (≤90 mg SC every ≥2 weeks for pediatrics) and reauthorization requires documented clinical benefit.

"Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH)."

Sign up to see full coverage criteria, indications, and limitations.